About Bennu Biotherapeutics

Bennu Biotherapeutics was founded in November 2021. We are dedicated to pioneering exploration and transformation in the field of cell therapy. We focus on developing innovative T-cell therapies for solid tumors and autoimmune diseases. Our product portfolio primarily consists of Tumor-Infiltrating Lymphocyte (TIL) therapy and Regulatory T-cell (Treg) therapy.

Our company has established a core technology platform that optimizes the rapid production process of TIL, significantly alleviates T-cell exhaustion through precise gene editing, enhances their persistence and potency, and modulates the tumor microenvironment to achieve stronger killing effects, thereby improving Patient prognosis.

Starting from original innovation, Bennu Biotherapeutics avoids homogeneous competition and fully leverages the company's long-term accumulation of advantages in industry, academia, and research. We aim to create globally pioneering and differentiated product lines, rapidly advance clinical development, and promote commercialization to bring hope to patients.

The company's development has been supported by numerous investments. We have completed two rounds of financing, angel round, and angel+ round, raising hundreds of millions of RMB. Investors include well-known institutions such as Hillhouse Capital, CD Capital, INCE Capital, Beijing Life Science Park Venture Capital, Witruth Capital, and Westlake Education Fund.